Afeyan: Replaced himself as CEO the day after closing $1 million
Noubar Afeyan · Moderna and Flagship Pioneering: Noubar Afeyan · Oct 11, 2021 · at 22:37
Noubar Afeyan recounts raising his first institutional round for PerSeptive Biosystems in his mid-20s and voluntarily stepping down as CEO.
0:00 / 0:18exact quote · 18.7s
720p mp4 · rendered on demand · StarZero watermark
“So what I decided to do is I kept talking to people until I found a firm to invest with me as the initial CEO, which is what I had been for the whole time, the year and a half before. And the day after we closed the million dollars, I went to them and I said, I don't want to be CEO. Let's go hire a CEO.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Noubar Afeyan
Afeyan: The romantic 'hero founder' startup folklore is largely unnecessary
“There's a lot of folklore in the startup world, which I'd say emphasizes the role of the individual. There's a hero kind of notion that's created, you know, against all odds. And here we were claiming that conceiving, creating, growing companies could be the o…”
Afeyan: Precision in guessing what works is unimportant when pioneering new fields
“The accuracy with which you have to guess what's going to work Is not at all important. Because we get into these brand new areas, it's wide open to find where value lies, right? Imagine if we waited three, four years as people did, or 10 years in the case of …”
Afeyan: Long biotech lifecycles prevent serial entrepreneurship, forcing internal talent creation
“In biotech, these companies have a half-life or a life cycle of, say, 10 years, 15 years. So people don't do one company after another. If they do one company after 1015 years and they succeed, they stop doing it. So you have to create the talent.”
Afeyan: Nobody took mRNA research seriously as recently as 2016
“Five years ago, nobody was taking MRNA research seriously”